The vision for the future of biopharmaceutical manufacturing calls for the development of flexible facilities and equipment that serve the production needs of an increasingly diverse portfolio of products for the prevention, treatment, and cure of chronic and deadly diseases. These new processes need to feature enhanced productivity, as well as reduced footprints and lower capital and operating costs, to ensure a robust supply chain and worldwide accessibility for these novel biologics. Finally, these new approaches demand the use of renewable raw materials and minimization of water and energy use.<br/><br/>This presentation will focus on the role that affinity purification methods are likely to play in this environment. New platforms and screening processes are being developed for the rapid identification and characterization of a wide variety of new affinity and pseudo-affinity ligands for an increasingly large variety of different targets from a broad range of new product modalities. In addition, there have been significant advances in the type of supports that are available for these affinity ligands, including membranes and monoliths of various types and morphologies. New hybrid and intensified affinity processes are being developed that utilize bind-and-elute, flow-through and continuous and semi-continuous formats. This lecture will review some of the more exciting advances in this area and will provide a perspective on future directions in this field.

Future of affinity purification in downstream processing: Novel ligands and supports

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.